SOLV
HealthcareSolventum
Price Chart
Market Data
Financials
XBRL · SEC EDGAR2022–2025(4yr)| Metric | FY 2022 | FY 2023 | FY 2024 | FY 2025Latest | YoY |
|---|---|---|---|---|---|
| Revenue | $8.1B | $8.2B | $8.3B | $8.3B | +0.9% |
| Gross Profit | $4.7B | $4.7B | $4.6B | $4.5B | -3.1% |
| Gross Margin | 57.7% | 57.3% | 55.6% | 53.5% | -2.2pp |
| Operating Income | $1.7B | $1.7B | $1.0B | $2.2B | +110.5% |
| Operating Margin | 20.8% | 20.6% | 12.6% | 26.2% | +13.6pp |
| Net Income | $1.3B | $1.3B | $479.0M | $1.6B | +224.8% |
| Net Margin | 16.5% | 16.4% | 5.8% | 18.7% | +12.9pp |
| Free Cash Flow | $1.4B | $1.6B | $805.0M | -$10.0M | -101.2% |
| FCF Margin | 17.6% | 19.8% | 9.8% | -0.1% | -9.9pp |
| EPS (Diluted) | $7.78 | $7.79 | $2.76 | $8.88 | +221.7% |
1. THE BIG PICTURE
Solventum is a high-margin legacy business currently trapped in a low-growth, high-leverage transition. While it leads its peer group in operating and net margins, its independence is presently a financial and legal burden—characterized by $5 billion in debt and a reliance on 3M infrastructure—rather than a catalyst for expansion.
2. WHERE THE RISKS HIT HARDEST
Solventum’s "70+ year history of discovering and innovating" (10-K Item 1) is directly threatened by its $5 billion debt load, which reduces the cash flow available for the very research and development needed to maintain that legacy (Risks). Furthermore, the "supply chain resiliency" and "vertically integrated operations" cited as competitive advantages (10-K Item 1) are undermined by the fact that 3M is the sole source for chemical materials used in products representing $3 billion of 2025 revenue (Risks). Finally, the "long-tenured customer relationships" Solventum relies on for "unique insights" (10-K Item 1) could be compromised by the "substantial costs" and potential inefficiencies of replicating IT and legal functions previously handled by 3M.
3. WHAT THE NUMBERS SAY TOGETHER
The financial data reveals a stark paradox: Solventum is the most profitable company in its peer group by operating margin (27.7%) and net margin (19.2%), yet it is the least efficient at generating cash, with a peer-bottom FCFFCFFree Cash Flow — cash left after paying for operations and capital investments; what the company can actually spend, save, or return to shareholders margin of 0.4% (XBRL). This suggests that the "solid performance" cited by management is being consumed by the friction of the spin-off and the interest requirements of its debt.
While Q4 2025 organic sales grew 3.5%, the trailing-twelve-month (TTMTTMTrailing Twelve Months — the most recent full year of financial data, updated on a rolling basis each quarter) revenue growth of 0.9% is the slowest among its peers (XBRL). This divergence is largely explained by the September 2025 divestiture of the Purification and Filtration business, which reduced total sales even as the core MedSurg and Dental segments showed underlying momentum (8-K). Management’s 2026 guidance of 2.0% to 3.0% organic growth suggests this modest recovery is expected to continue, though it remains well below the growth rates of peers like Zimmer Biomet (+7.2%).
4. IS IT WORTH IT AT THIS PRICE?
At 9.5x Forward P/EP/EPrice-to-Earnings ratio — share price divided by annual earnings per share; how much investors pay per dollar of profit. Higher P/E = higher growth expectations, Solventum trades at a 36% discount to the peer median of 14.9x. This "cheapest" status is a direct reflection of Solventum's stagnant TTMTTMTrailing Twelve Months — the most recent full year of financial data, updated on a rolling basis each quarter growth and the "Elevated" risk of its $5 billion debt (Risks). For this valuation to be justified, Solventum must prove it can maintain its 27.7% operating margins while operating independently of 3M’s infrastructure. The market is pricing in very little long-term growth, which is consistent with the 2026 organic growth guidance that excludes approximately 100 basis points of impact from intentional SKU exits (8-K).
5. WHAT WOULD CHANGE THIS VIEW?
- Cautious if the FCFFCFFree Cash Flow — cash left after paying for operations and capital investments; what the company can actually spend, save, or return to shareholders margin remains near 0.4%, as this would indicate Solventum cannot comfortably service its $5 billion debt while funding the Acera acquisition or future growth.
- Constructive if organic growth exceeds the 4.0% upper-end guidance (excluding SKU exits), signaling that the MedSurg and Dental portfolios are successfully gaining market share as an independent entity.
- Cautious if any disruptions occur in the 3M supply transition, directly impacting the $2 billion in revenue tied to proprietary 3M manufacturing processes.
6. BOTTOM LINE
Structural Advantage: Deep clinical integration and industry-leading operating margins across a diversified portfolio of MedSurg and Dental material science.
Bottom Line: Solventum is a profitable but cash-constrained legacy spin-off that remains too tethered to its former parent’s supply chain to be viewed as a de-risked investment.
1. Top 5 Material Risks
- Debt Obligations: Solventum carries approximately $5 billion in outstanding indebtedness as of December 31, 2025, which reduces cash flow available for capital expenditures, limits financial flexibility, and increases vulnerability to adverse economic conditions.
- Sole-Source Dependency on 3M: 3M is the sole supplier for chemical materials and inputs used in products representing approximately $3 billion of 2025 revenue, including a proprietary manufacturing process for products accounting for $2 billion of revenue.
- Separation and Transition Costs: Solventum may fail to achieve the expected benefits of the spin-off, while simultaneously incurring substantial costs to replicate corporate functions (IT, legal, accounting) previously provided by 3M, which may be less efficient or more expensive than historical allocations.
- Tax Indemnification: Under the Tax Matters Agreement, Solventum is required to indemnify 3M for material taxes resulting from the spin-off if certain post-spin-off transactions—such as acquisitions or equity issuances—cause the distribution to be taxable.
- Regulatory Compliance and Product Liability: Solventum operates in a strictly regulated healthcare environment where failure to comply with laws (such as the False Claims Act or anti-kickback statutes) or the occurrence of product liability claims could result in significant fines, product recalls, or exclusion from government healthcare programs.
2. Company-Specific Risks
- PFAS Liabilities: While 3M indemnifies Solventum for certain PFAS-related liabilities through 2025, Solventum remains responsible for liabilities arising from its own operations thereafter, and the potential for future regulatory restrictions on PFAS-containing components poses a material risk to its product portfolio.
- Restructuring Execution: The "Transform for the Future" multiyear restructuring program carries the risk of implementation costs exceeding projections and potential loss of operational continuity or accumulated knowledge during the transition.
- AI and Emerging Technology Integration: The deployment of AI in products like those in the Health Information Systems segment introduces risks related to algorithmic flaws, data privacy, and the potential for competitors to gain market share through faster adoption of these technologies.
- Anti-Takeover Provisions: Provisions in the certificate of incorporation and bylaws, including a classified board until 2028 and the inability of shareholders to call special meetings, may deter acquisition attempts that shareholders might otherwise favor.
3. Regulatory/Legal Risks
- Healthcare Fraud and Abuse: Solventum is subject to the Physician Payments Sunshine Act, the False Claims Act, and anti-kickback laws; non-compliance can lead to criminal or civil financial penalties and exclusion from Medicare and Medicaid.
- Data Privacy: Solventum must comply with global regulations including HIPAA, GDPR, and China’s PIPL; failure to safeguard sensitive health and personal information can result in onerous investigations and private litigation.
- Environmental Regulations: Solventum faces increasing compliance burdens from mandatory sustainability reporting (e.g., EU Corporate Sustainability Reporting Directive) and potential future taxes on carbon-intensive inputs or energy.
- Antitrust: Regulatory authorities may impose fines or require changes to business practices if Solventum is found to have engaged in anti-competitive conduct, and private rights of action from competitors could lead to significant litigation expenses.
4. Financial Impact Map
Debt Service Obligations → Cash Flow from Operations → Requires a substantial portion of cash flow to make interest payments and limits funds for capital expenditures. 3M Sole-Source Supply → Revenue → $3 billion of fiscal year 2025 revenue is at risk if 3M fails to satisfy supply requirements. Separation-Related Costs → Operating Expenses → Increased accounting, tax, legal, and professional services costs as a standalone public company. Tax Indemnification → Cash and Cash Equivalents / Retained Earnings → Potential material payments to 3M for tax liabilities if the spin-off is deemed a taxable transaction. Product Recalls/Liability → Operating Expenses / Legal Reserves → Significant costs associated with product recalls, safety alerts, or legal settlements that may exceed insurance coverage.
Recent Filings
| Form | Filed | Period |
|---|---|---|
| 10-K | Feb 2026 | Dec 2025 |
| 8-K | Feb 2026 | — |
| 10-Q | Nov 2025 | Sep 2025 |
| 14A | Mar 2025 | — |
AI-extracted key facts from press releases and SEC filings. Significance 1–10.
Solventum Q1 sales -3.0%, organic sales +2.1%, affirms FY26 guidance
- ▸Q1 total sales decreased 3.0% year-over-year
- ▸Organic sales growth of 2.1% reported for the quarter
- ▸Affirmed full-year 2026 organic sales growth guidance
- ▸Affirmed full-year 2026 free cash flow guidance
- ▸Adjusted EPS expected toward high end of existing range
Solventum Q1 revenue $2.01B beats estimates, adjusted EPS $1.48 tops consensus
- ▸Q1 revenue $2.01B, down 3% YoY, beat estimates by 1.9%
- ▸Adjusted EPS $1.48, beat analyst consensus of $1.35 by 9.3%
- ▸Adjusted EBITDA $267M, missed analyst estimates of $426.1M
- ▸Operating margin 4%, down from 7.3% in prior year period
- ▸FY Adjusted EPS guidance reiterated at $6.50 midpoint
Solventum Q1 Adjusted EPS $1.48 +10.6%, Affirms Full-Year Guidance
- ▸Q1 sales $2.0B, -3.0% reported but +2.1% organic growth
- ▸Adjusted diluted EPS $1.48, up 10.6% YoY
- ▸Affirmed FY26 organic sales growth guidance of 2.0% to 3.0%
- ▸FY26 adjusted EPS expected toward high end of $6.40–$6.60 range
- ▸Q1 free cash flow $(273)M, impacted by separation and transition costs
Solventum opens new $200 million Innovation Hub in Eagan, Minnesota
- ▸Opened $200 million state-of-the-art Innovation Hub in Eagan, MN
- ▸Facility consolidates operations from three former 3M locations
- ▸Employs over 1,800 staff members in Minnesota
- ▸Hub features R&D capabilities, quality lab, and pilot factory
- ▸Solventum spun off from 3M as independent entity on April 1, 2024
Solventum FY earnings beat top-line expectations; Jefferies maintains Buy rating
- ▸FY top-line results slightly surpassed analyst expectations
- ▸Adjusted EBITDA exceeded consensus estimates despite missing Jefferies' forecast
- ▸Jefferies reiterates Buy rating with $32 price target
- ▸CIBC reiterates Outperformer rating with $37 price target
- ▸Management considering potential M&A activity in 2026 to increase scale
Solventum Q4 Revenue $2B beats estimates, EPS $0.36 misses expectations by 37%
- ▸Q4 revenue $2B, down 3.7% YoY, beat estimates of $1.96B
- ▸Q4 EPS $0.36, missed analyst estimates of $0.57
- ▸Shares down 25.4% from 52-week high of $88.20
- ▸Stock down 19.4% over the past three months
- ▸Consensus analyst rating remains Moderate Buy with $93.45 price target